Vertex Pharmaceuticals
VRTX
386 hedge funds and large institutions have $16.5B invested in Vertex Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 134 increasing their positions, 161 reducing their positions, and 57 closing their positions.
22% more call options, than puts
Call options by funds: $388M | Put options by funds: $319M
2% less capital invested
Capital invested by funds: $16.8B → $16.5B (-$262M)
4% less funds holding
Funds holding: 403 → 386 (-17)
17% less repeat investments, than reductions
Existing positions increased: 134 | Existing positions reduced: 161
30% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 57
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$309M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$171M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$128M |
| 4 |
JP Morgan Chase
New York
|
+$108M |
| 5 |
ClearBridge Investments
New York
|
+$70.6M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$231M |
| 2 |
Goldman Sachs
New York
|
-$133M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$120M |
| 4 |
Neuberger Berman Group
New York
|
-$73.9M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$63M |
VRTX Hedge Fund Activity: Q4 2013 in Review
386 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2013, worth a combined $16.5B — down 1.6% from $16.8B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of VRTX and 40 opened new positions — a net loss of 17 holders — while 161 trimmed existing stakes and 134 added.
The largest buyer was Wellington Management Group, adding an estimated $309M. The largest seller was Fidelity Investments, cutting an estimated $231M.
- 386 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2013, down from 403 in Q3 2013.
- Funds reported $16.5B of Vertex Pharmaceuticals stock for Q4 2013, down 1.6% quarter-over-quarter.
- 40 funds opened new Vertex Pharmaceuticals positions in Q4 2013 and 57 closed out, a net change of -17 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2013 was Wellington Management Group, an estimated $309M added.
- The largest Vertex Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $231M sold.
Based on aggregated 13F filings for Q4 2013.